European Commission

Non-small cell lung cancer
#Bispecific Antibodies #European Commission #Johnson & Johnson #Non-small cell lung cancer (NSCLC) #Oncology

Bispecific antibody combo for NSCLC could extend life by a year

The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).  It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R)… Read More

#News #Regulatory

Lung cancer
#European Commission #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC)

EC approves chemo-free combination for mutated NSCLC 

The European Commission (EC) has extended the approval for Rybrevant (amivantamab), in combination with Lazcluze (lazertinib), to the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC).  It is specifically approved for use in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon… Read More

#News #Regulatory

Stamp of approval
#AstraZeneca #European Commission #Phase III trial #Rare disease

EU approves new indication for AstraZeneca’s Fasenra

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval by… Read More

#News #Regulatory

#Biological threats #Covid-19 #European Commission #Fabentech #Funding #Pandemic response

€20 million EIB financing to combat biological threats

The European Investment Bank (EIB) and the French biopharmaceutical company Fabentech have signed a €20 million loan to accelerate the development of broad-spectrum therapeutics to combat biological threats to public health. The deal is supported by the Health Emergency Preparedness and Response Authority (HERA), set up… Read More

#News

Human liver
#European Commission #Ipsen #Liver disease #Phase III trial #Rare disease

EU approves first new treatment for rare liver disease in a decade

The European Commission has conditionally approved Iqirvo (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). The approval is limited to adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. Iqirvo is a first-in-class,… Read More

#News #Regulatory

#Cereno Scientific #European Commission #Hypertension #Orphan drugs #Rare disease

EU orphan designation for pulmonary hypertension drug

The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed to offer improved quality of life and prolonged life for patients with PAH. Companies that obtain… Read More

#News #Regulatory

Non-small cell lung cancer
#European Commission #Lung cancer #Oncology #Phase II trial #Pierre Fabre

EC approves new combination treatment for NSCLC

The European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The EC decision followw a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25… Read More

#News #Regulatory

Urinary system
#Antibody drug conjugate (ADC) #Astellas Pharma #European Commission #Oncology #Urothelial carcinoma

EU okays new first-line treatment for advanced urothelial cancer

The European Commission has granted marketing authorisation for antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in combination with PD-1 inhibitor Keytruda (pembrolizumab) for urothelial cancer. It is approved for the first-line treatment of adult patients with unresectable or metastatic cancer, who are eligible for platinum-containing chemotherapy. The approval is based on… Read More

#News #Regulatory

#BioNTech #Cancer immunotherapy #Cancer vaccine #European Commission #Immunology / Virology & Vaccines #mRNA #University College London Hospitals

First patient dosed in UK novel cancer vaccine trial

A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.  It is the first time this immunotherapy made by BioNTech will be studied in a clinical… Read More

#Cancer Research #News

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

New DDW Highlights podcast: 27 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a busy week for medical regulatory agencies, with a number of key… Read More

#News

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

New DDW Highlights vodcast: 27 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   It’s been a busy week… Read More

#News

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

This week in drug discovery (19-23 August) 

News round-up for 19-23 August by DDW Senior Digital Content Editor Diana Spencer. It’s been a busy week for medical regulatory agencies, with a number of key decisions made on therapies for graft-versus-host-disease, neuroendocrine carcinoma, haemophilia B, lymphoma and non-small cell lung cancer. The top stories:… Read More

#News

Monoclonal antibody
#AbbVie #European Commission #Follicular lymphoma #Genmab #Lymphoma #Oncology

Second lymphoma indication approval for Tepkinly in Europe

AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody approved to treat both… Read More

#News #Regulatory

Endometrial biopsy
#AstraZeneca #European Commission #Immunotherapy #Oncology #PARP inhibitors #Phase III trial

Lynparza and Imfinzi combination approved in the EU for endometrial cancer

AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease. Imfinzi plus… Read More

#News #Regulatory #Trending News

The European Medicines Agency in Amsterdam
#CAR-T #Cell therapy #European Commission #European Medicines Agency #Kite Pharma

EU relaxes safety monitoring of CAR-T therapies

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T cell therapy infusion from… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #European Commission #Janssen #Myeloma #Oncology #Phase III trial

EC expands use of BCMA-targeted CAR-T therapy

The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). It is approved in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor… Read More

#News #Regulatory